Evaluation of Ultrathin Strut Sirolimus-eluting Stent with Bioabsorbable Polymer
in Patients on Long-term Oral Anticoagulation Undergoing Coronary Revascularization
Led by Fundación EPIC · Updated on 2026-08-06
500
Participants Needed
13
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on patients with coronary artery disease and ischemic heart disease who are receiving chronic oral anticoagulation and need percutaneous coronary revascularization with stent implantation. Because these patients require antiplatelet therapy, they face a high risk of bleeding. The study evaluates a new generation ultrathin strut sirolimus-eluting stent with a bioabsorbable polymer, which may allow for shorter antiplatelet treatment regimens and could be a suitable option for these high-bleeding risk patients.
Participants receive treatment using the Supraflex Cruz Sirolimus-eluting stent during a percutaneous coronary intervention PCI for de novo coronary artery stenosis. This observational study monitors patients who have had this specific stent implanted, without randomization or placebo comparison, focusing on the real-world use of this device. No other stents are used within 6 months before or during the procedure, and the stent is the single device evaluated.
During the study, participants are followed for up to 12 months to assess outcomes such as Net Adverse Clinical Events NACE, Major Adverse Cardiac Events MACE, Target Lesion Failure TLF, death, acute myocardial infarction, stroke, and target vessel revascularization. Follow-up includes monitoring clinical events and ensuring participant safety. The total study duration extends until March 2029, with a primary completion date in March 2027.
CONDITIONS
Brief Title
Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
Research Team
J
Juan Gabriel Córdoba Soriano, MD, PhD
F
FUNDACION EPIC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Receiving chronic oral anticoagulation treatment for any reason
Diagnosed with de novo coronary artery disease requiring elective or urgent percutaneous revascularization
Treatment includes implantation of an ultrathin strut sirolimus-eluting stent with bioabsorbable polymer
You will not qualify if you...
Treatment with any stent other than the Supraflex Cruz in the 6 months before the current procedure
Use of other types of stents in the same or scheduled procedure for other vessels
Treatment for restenosis or stent thrombosis
Presentation with cardiogenic shock or after cardiorespiratory arrest
Allergy to any component of the stent
Inability to participate in follow-up
Life expectancy less than 1 year
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Single procedure
Participants receive the Supraflex Cruz sirolimus-eluting stent during percutaneous coronary intervention for coronary artery disease.
1 procedure visit
Follow-up
Duration - Up to 12 months
Participants are monitored for up to 12 months for clinical events including cardiac events, strokes, and vessel revascularization.
Regular follow-up visits during 12 months
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Evaluating Myocardial Viability in Ischemic Heart Disease Using Integrated 18F-FDG PETMR Imaging Before Surgery
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Evaluating a New Cardiac Rehabilitation Approach for Adults With Ischemic Heart Disease
A Prospective, Randomized Controlled Study Comparing New and Traditional Therapies
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Study on Ultrasound Screening and Combined Treatments for Patients With Coronary and Head and Neck Artery Narrowing
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Comparison of Supraflex Cruz 60 μm Versus Ultimaster Tansei 80 μm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial.
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
Azfar Zaman, Robbert J de Winter, Norihiro Kogame...
Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry.
Pedro A Lemos, Prakash Chandwani, Sudheer Saxena...